KFDA to raise preliminary review fees for clinical studies.

The KFDA newly adopted the authorization system for the protocol of clinical studies, and plans to have its explanatory meeting for the R&D responsible members of the respective pharmaceutical firms at the KPMA auditorium at 3 p.m. on Feb. 19.

In the meeting the KFDA may explain the revised working rules of the pharmaceutical affairs act and the detailed guidelines and action plans for the ...